NxStage Presents New Findings on Lowering HHD Attrition Through Nx2me Connected Health Technology and Increased Training Volume
Research Focused on Helping Patients Succeed on Home Hemodialysis Will Be Presented at the Annual Dialysis Conference
LAWRENCE, Mass., Feb. 24, 2016 /PRNewswire/ -- During the 2016 Annual Dialysis Conference (ADC) in Seattle from February 27 – March 1, NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, will be presenting abstracts highlighting benefits of its Nx2me® Connected Health technology as well as those seen in programs with increased home hemodialysis (HHD) training volume. Featured speakers include Dr. Eric Weinhandl, contract Epidemiologist to NxStage and Adjunct Assistant Professor at the University of Minnesota, and Dr. Allan J. Collins, NxStage Senior Medical Advisor and Professor of Medicine at the University of Minnesota.
In the first abstract presented, a study of 328 NxStage HHD patients using Nx2me showed a 44% reduction in controllable dropout compared with the matched non-Nx2me HHD patients. Nx2me is a state of the art telehealth platform for the collection and delivery of treatment and medical information using an iPad® or iPad mini. Nx2me transmits data to providers after each treatment session, and enables providers to review the data in the Nx2me Clinician Portal. This gives the care team enhanced capabilities to review and follow the patients' treatment adherence and progress as well as the ability to transfer this data directly into their electronic medical record and billing systems.
The second abstract using data on 11,153 patients trained in 1,108 centers from NxStage's ongoing patient registry demonstrates how increasing HHD program training volume is associated with increased incidence of kidney transplantation and decreased patient dropout from home hemodialysis due to patient burden and psychosocial issues.
"With these findings, we hope to educate the attending medical community both on practices for increasing home hemodialysis patient retention, and the technological advancements NxStage is implementing to help more patients reap the benefits associated with home hemodialysis therapy," said Dr. Weinhandl.
"Home hemodialysis therapy, particularly when done more frequently, clearly has life-changing benefits. Because the training required to go home involves investment of time for both the dialysis provider and the patient, it is essential that training is efficient and that patients are able to continue to do their dialysis at home for as long as they can," said Joseph E. Turk, president of NxStage. "We're delighted that our depth of experience and our investment in breakthrough technologies with Nx2me allow us to give providers additional tools to optimize their and their patients' successes."
The abstracts will be presented on Monday, February 29th at 11:00am and 11:30am respectively.
For more information about the System One, please visit www.nxstage.com.
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and simplify alternative site care. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com and www.nxstagekidneycare.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
Tel: (978) 332-5923
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-presents-new-findings-on-lowering-hhd-attrition-through-nx2me-connected-health-technology-and-increased-training-volume-300225173.html
SOURCE NxStage Medical, Inc.